Roth Capital analyst Boobalan Pachaiyappan tells investors in a research note that the FDA’s intention not to require an Ad Comm “at this time” for deramiocel for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy “may not necessarily be positive news,” and that it believes a promissory Ad Comm meeting would be positive, as a potential positive Ad Comm panel vote would put pressure on the new leadership to approve deramiocel in its current form. The firm reiterates a Buy rating and $31 price target on Capricor shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright
- HHS spokesperson tells Reuters FDA ‘actively re-evaluating’ Capricor AdCom
- Capricor Therapeutics provides regulatory update on Deramiocel BLA
- Roth says ‘excessive’ Capricor selloff due to ‘investor overreaction’
- Capricor selloff brings buying opportunity, says H.C. Wainwright